Stockscreener 앱 받기
9.25
1.09%
0.10
Lyell Immunopharma Inc 주식(LYEL)의 최신 뉴스
Lyell’s lymphoma therapy shows high response rate in trial - Investing.com
Lyell’s lymphoma therapy shows high response rate in trial By Investing.com - Investing.com Nigeria
Lyell Immunopharma Announces Promising CAR T-Cell Trial Data - TipRanks
Lyell Immunopharma Says LYL314 Shows 'Robust' Responses in Large B-Cell Lymphoma Trial - marketscreener.com
Lyell Immunopharma (LYEL) Releases Promising Results from LYL314 Trial | LYEL Stock News - GuruFocus
Lyell Immunopharma Announces Positive Clinical Data From Phase 1/2 Trial Of Lyl314 For The Treatment Of Aggressive Large B-Cell Lymphoma - MarketScreener
Lyell Immunopharma Announces Positive New Clinical Data - GlobeNewswire
Lyell Immunopharma (LYEL) Strengthens Leadership Team with Key A - GuruFocus
Lyell Immunopharma (LYEL) Announces Key Executive Appointments | LYEL Stock News - GuruFocus
Lyell Immunopharma Expands Board, Appoints New Director - TipRanks
Lyell Immunopharma Strengthens Clinical And Commercial Capabilities With Key Board And Executive Appointments - marketscreener.com
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments - GlobeNewswire
Lyell Immunopharma Strengthens Leadership: Key Hires from BMS, Amgen Shape CAR T-cell Future - Stock Titan
Lyell Immunopharma (NASDAQ:LYEL) Raised to Hold at Wall Street Zen - Defense World
From Collapse to Comeback: Lyell Immunopharma’s Stock Surge Signals Turning Point - FXLeaders
From Collapse to Comeback: Lyell Immunopharma's Stock Surge Signals Turning Point—Cancer Breakthrough? - FXLeaders
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference - GlobeNewswire
Lyell Immunopharma Showcases Next-Gen Cancer Therapies at Major Goldman Sachs Healthcare Event - Stock Titan
Imugene CMO and CEO talk trial momentum and immuno-oncology progress - Proactive Investors
Layoff Tracker: Keros Cuts 45% of Workforce Along With Pulmonary Hypertension Drug - BioSpace
Lyell Immunopharma (LYEL) Trading Resumes with Renewed Focus | L - GuruFocus
Lyell Immunopharma (LYEL) Faces Trading Halt Due to Volatility | - GuruFocus
Lyell Immunopharma (LYEL) Faces Trading Halt Due to Volatility | LYEL Stock News - GuruFocus
Morgan Stanley, Walmart, Pfizer and more: Full list of over 150 American companies laying off employees in June - The Economic Times
Samsung may incorporate Perplexity's AI tech in its phones - Yahoo News
UK Government announced funding for NHS hospital maintenance - Yahoo
Electricity prices rise in the summer. What can you do? - Yahoo
Dai-ichi Life to acquire 15% stake in British insurer M&G - Yahoo
Should You Buy AGNC Investment While It's Below $10? - Yahoo
Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy? - Yahoo
Diakonos Oncology secures $20m for Phase II trial of glioblastoma treatment - Yahoo
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Grows Stock Position in Enhabit, Inc. (NYSE:EHAB) - Defense World
Deutsche Bank AG Grows Stock Holdings in LCNB Corp. (NASDAQ:LCNB) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Stock Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Deutsche Bank AG Invests $244,000 in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Markel Group Inc. (NYSE:MKL) Stake Lifted by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 36,555 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $146,000 Stake in Grab Holdings Limited (NASDAQ:GRAB) - Defense World
Tiptree Inc. (NASDAQ:TIPT) Shares Sold by Millennium Management LLC - Defense World
Cetera Investment Advisers Grows Stock Holdings in Immersion Co. (NASDAQ:IMMR) - Defense World
Mondelez sues Aldi over packaging similarities - Yahoo
Report: Airbnb brought $900M to Louisiana in 2024 - Yahoo News
BNP Paribas Financial Markets Takes $162,000 Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Lyell Immunopharma (NASDAQ:LYEL) vs. Astellas Pharma (OTCMKTS:ALPMY) Critical Review - Defense World
Lyell Immunopharma (LYEL) Trading Pause Ahead of Important Annou - GuruFocus
Northern Trust Corp Sells 45,853 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Imugene appoints Dr John Byon as chief medical officer to lead next phase of clinical development - Proactive Investors
Lyell Immunopharma Announces 1-for-20 Reverse Stock Split - TipRanks
D. E. Shaw & Co. Inc. Boosts Stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Lyell Immunopharma Stockholders Approve Key Proposals - TipRanks
Lyell Immunopharma: Q1 Earnings Snapshot - The Washington Post
Lyell Immunopharma Advances CAR T-Cell Therapy Pipeline - TipRanks
Lyell Immunopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Lyell Immunopharma Reports Clinical Progress and Financial Results for LYL314 CAR T-Cell Therapy Targeting Relapsed/Refractory Large B-Cell Lymphoma - Nasdaq
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025 - GlobeNewswire
Breakthrough Lymphoma Treatment: Lyell's Dual-Target Therapy Achieves 94% Response Rate in Clinical Trial - Stock Titan
LYELLyell Immunopharma, Inc. Latest Stock News & Market Updates - Stock Titan
Lyell Immunopharma (LYEL) to Release Quarterly Earnings on Monday - Defense World
JPMorgan Chase & Co. Buys 336,516 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
LYEL’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Lyell Immunopharma Announces Oral Presentation of New - GlobeNewswire
Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025 - Stock Titan
1.80%
0.18%
자본화:
|
볼륨(24시간):